Effect of Genetic Polymorphisms on Platinum Based Chemotherapy in Non Small Cell Lung Cancer

Effect of Genetic Polymorphisms on Clinical Outcome of Platinum Based Chemotherapy in Non-Small Cell Lung Cancer Patients

This Study evaluate the effect of Polymorphism in the Excision repair cross-complementing group 5 (ERCC5) (rs1047768 and rs751402) gene on the clinical outcome of Platinum-based regimens used in the treatment of Non-Small Cell Lung Cancer (NSCLC) patients

Inclusion Criteria:

1. Newly diagnosed with immunohistochemically and pathologically confirmed non-small cell lung cancer (NSCLC).
2. Eastern Cooperative Oncology Group performance status (ECOG PS) = 0-2.
3. Chemotherapy naïve.
4. Age >18 years.
5. Adequate bone marrow reserve

Exclusion Criteria:

1. Presence of Central nervous system(CNS) metastases.
2. Inadequate liver function
3. Inadequate renal function
4. Serious comorbid systemic disorder incompatible with the study.
5. Pregnancy